As one of few Swedish companies, Uppsala-based Orexo has made the leap to commercialize its star product for treating opioid addiction in the US, even before entering the European market. In this interview, CEO Nikolaj Sørensen highlights the impact of Orexo in finding solutions to tackle the US opioid crisis, gives an update on company’s patent litigation case and underlines the benefits of operating in an innovation-friendly Swedish ecosystem.
Even the President of the United States of America has called the opioid crisis a public health emergency and made it a high priority. Orexo is proud of taking significant responsibility for finding solutions to the crisis - far more when what is expected from companies of our size.
